<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01273233</url>
  </required_header>
  <id_info>
    <org_study_id>EV71-1001-Ia</org_study_id>
    <nct_id>NCT01273233</nct_id>
  </id_info>
  <brief_title>Safety of an Inactivated Enterovirus Type 71 Vaccine in Healthy Adults</brief_title>
  <official_title>A Blinded, Randomized and Controlled Clinical Trial of An Inactivated Enterovirus Type 71 Vaccine in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sinovac Biotech Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sinovac Biotech Co., Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A blind, randomized and placebo-controlled clinical trial with Inactivated Enterovirus Type&#xD;
      71 Vaccines in healthy adults&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 36 eligible subjects aged from 18 to 49 years will be enrolled in the study, they&#xD;
      will be randomized to receive two different dosage of vaccine candidate or placebo to&#xD;
      evaluate the safety of this vaccine in adults&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of the inactivated Enterovirus Type 71 Vaccine in adults by different doses</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Infection; Viral, Enterovirus</condition>
  <arm_group>
    <arm_group_label>Group 1: 200U EV71 vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 adults received 3 doses of 200U EV71 vaccine 14 days apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: 400U EV71 vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 adults received 3 doses of 400U EV71 vaccine 14 days apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>6 adults received 3 doses of placebo 14 days apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>6 adults received 3 doses of placebo 14 days apart</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Inactivated Enterovirus Type 71 Vaccine</intervention_name>
    <description>A Sinovac EV71 vaccine contains inactivated EV71 virus, aluminum hydroxide, sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate and injection water. The EV71 vaccine is supplied in one mono-dose vial containing 0.5 mL of viral suspension with EV71 virus antigen of 200U and 400U (Elisa unit)</description>
    <arm_group_label>Group 1: 200U EV71 vaccine</arm_group_label>
    <arm_group_label>Group 2: 400U EV71 vaccine</arm_group_label>
    <other_name>EV71 Vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo is suspension with a little ivory precipitation, composition of which is aluminum hydroxide diluents.</description>
    <arm_group_label>Group 1: Placebo</arm_group_label>
    <arm_group_label>Group 2: Placebo</arm_group_label>
    <other_name>EV71 Vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy males and females, aged from 18 to 49 years old. Health is determined by&#xD;
             medical history, physical examination, laboratory examination and clinical judgment of&#xD;
             the investigator&#xD;
&#xD;
          2. Provided legal identification for the sake of recruitment.&#xD;
&#xD;
          3. Subjects are able to understand and sign informed consents.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Histroy of Hand-foot-mouth Disease&#xD;
&#xD;
          2. Women of lactation, pregnancy or about to be pregnant in 60 days&#xD;
&#xD;
          3. Subject that has allergic history of vaccine, or allergic to any ingredient of vaccine&#xD;
&#xD;
          4. Serious adverse reactions to vaccines such as anaphylaxis, hives, respiratory&#xD;
             difficulty, angioedema, or abdominal pain&#xD;
&#xD;
          5. Congenital malformations or developmental disorders, genetic defects, or severe&#xD;
             malnutrition&#xD;
&#xD;
          6. Epilepsy, seizures or convulsions history, or family history of mental illness&#xD;
&#xD;
          7. Autoimmune disease or immunodeficiency, or parents, brothers and sisters have&#xD;
             autoimmune diseases or immunodeficiency&#xD;
&#xD;
          8. History of asthma, angioedema, diabetes or malignancy&#xD;
&#xD;
          9. History of thyroidectomy or thyroid disease that required medication within the past&#xD;
             12 months&#xD;
&#xD;
         10. Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or&#xD;
             platelet disorder requiring special precautions) or significant bruising or bleeding&#xD;
             difficulties with IM injections or blood draws&#xD;
&#xD;
         11. Asplenia, functional asplenia or any condition resulting in the absence or removal the&#xD;
             spleen&#xD;
&#xD;
         12. Acute illness or acute exacerbation of chronic disease within the past 7 days&#xD;
&#xD;
         13. Any history of immunosuppressive medications or cytotoxic medications or inhaled&#xD;
             corticosteroids within the past six months (with the exception of corticosteroid nasal&#xD;
             spray for allergic rhinitis or topical corticosteroids for an acute uncomplicated&#xD;
             dermatitis)&#xD;
&#xD;
         14. History of any blood products within 3 months&#xD;
&#xD;
         15. Administration of any live attenuated vaccine within 28 days&#xD;
&#xD;
         16. Administration of subunit or inactivated vaccines ,e.g., pneumococcal vaccine, or&#xD;
             allergy treatment within 14 days&#xD;
&#xD;
         17. Axillary temperature &gt; 37.0 centigrade before vaccination&#xD;
&#xD;
         18. Abnormal laboratory parameters before vaccination&#xD;
&#xD;
         19. Any medical, psychiatric, social condition, occupational reason or other&#xD;
             responsibility that, in the judgment of the investigator, is a contraindication to&#xD;
             protocol participation or impairs a volunteer's ability to give informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yan-ping Li, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangxi Centers for Disease Control and Prevention</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GuangXi Center for Diseases Control and Prevention</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <study_first_submitted>January 7, 2011</study_first_submitted>
  <study_first_submitted_qc>January 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2011</study_first_posted>
  <last_update_submitted>March 13, 2013</last_update_submitted>
  <last_update_submitted_qc>March 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enterovirus Infections</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

